“This study highlights how treatment remains influenced by where you live,” Diana Magee, MD, MPH, MSc.
In this video, Diana Magee, MD, MPH, MSc, summarizes the 2022 Society of Urologic Oncology Annual Meeting presentation, “Geographic variation in utilization of doublet therapy for metastatic prostate cancer.” Magee is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.